Cellosaurus PLC/PRF/5 (CVCL_0485)

Cell line name PLC/PRF/5
Synonyms PLC-PRF-5; PLC PRF 5; PLC/PRF5; PLCPRF5; PLC-8024; PLC8024; PLC; Alexander cells; Alexander; Primary Liver Carcinoma/Poliomyelitis Research Foundation/5
Accession CVCL_0485
Secondary accession CVCL_6714
Resource Identification Initiative To cite this cell line use: PLC/PRF/5 (RRID:CVCL_0485)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: JFCR45 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Characteristics: Contains at least 7 copies of integrated HBV genomes.
Characteristics: Secretes hepatitis virus B surface antigen (HBsAg).
Characteristics: Has lost chromosome Y.
Doubling time: 35-40 hours (PubMed=63998).
Sequence variation: TP53 p.Arg249Ser (PubMed=8389256).
Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024.
Misspelling: PCL/PRF/5; In Cosmic 873402.
Disease Hepatocellular carcinoma (NCIt: C3099)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_B449 (NPLC/PRF/5); CVCL_LJ87 (PLC/PRF/5 Luciferase/GFP)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; CLS; ECACC; JCRB; KCLB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10
D13S31711,12
D16S53913
D18S5117
D21S1130,33.2
D3S135815
D5S81812
D7S8209,11 (ATCC; ECACC; JCRB; KCLB; PubMed=25877200)
9 (CLS)
D8S117913,16
FGA25 (CLS)
19.2,25 (KCLB; PubMed=25877200)
Penta D6,10
Penta E10,16
TH018 (ATCC)
7,8 (CLS; ECACC; JCRB; KCLB; PubMed=25877200)
TPOX8
vWA15,16
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=63998
Alexander J.J., Bey E.M., Geddes E.W., Lecatsas G.
Establishment of a continuously growing cell line from primary carcinoma of the liver.
S. Afr. Med. J. 50:2124-2128(1976)

PubMed=184551
Alexander J.J., Bey E.M., Whitcutt J.M., Gear J.H.S.
Adaptation of cells derived from human malignant tumours to growth in vitro.
S. Afr. J. Med. Sci. 41:89-98(1976)

PubMed=187208; DOI=10.1038/bjc.1976.205
MacNab G.M., Alexander J.J., Lecatsas G., Bey E.M., Urbanowicz J.M.
Hepatitis B surface antigen produced by a human hepatoma cell line.
Br. J. Cancer 34:509-515(1976)

PubMed=6160110
Daemer R.J., Feinstone S.M., Alexander J.J., Tully J.G., London W.T., Wong D.C., Purcell R.H.
PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity.
Infect. Immun. 30:607-611(1980)

PubMed=6268737; DOI=10.1099/0022-1317-53-1-105
Oefinger P.E., Bronson D.L., Dreesman G.R.
Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.
J. Gen. Virol. 53:105-113(1981)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)

PubMed=6889516; DOI=10.1016/0277-5379(82)90010-4
Sattler F.R., Paolucci S., Kreider J.W., Ladda R.L.
A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice.
Eur. J. Cancer Clin. Oncol. 18:381-389(1982)

PubMed=6555060; DOI=10.1007/BF00199162
Keong A., Herman J., Rabson A.R.
Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity.
Cancer Immunol. Immunother. 15:183-187(1983)

PubMed=6225510; DOI=10.1007/BF00199161
Keong A., Rabson A.R.
Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells.
Cancer Immunol. Immunother. 15:178-182(1983)

PubMed=2414854
Aspinall S., Alexander J.J.
Hepatitis B virus gene expression in two cell lines, one derived from a natural human infection, the other experimentally infected in vitro.
S. Afr. Med. J. 68:751-754(1985)

PubMed=2992761; DOI=10.1016/0165-4608(85)90033-0
Pinto M.R., Bey E., Bernstein R.
The PLC/PRF/5 human hepatoma cell line. I. Reevaluation of the karyotype.
Cancer Genet. Cytogenet. 18:11-18(1985)

PubMed=2992762; DOI=10.1016/0165-4608(85)90034-2
Bowcock A.M., Pinto M.R., Bey E., Kuyl J.M., Dusheiko G.M., Bernstein R.
The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites.
Cancer Genet. Cytogenet. 18:19-26(1985)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=1661347; DOI=10.2302/kjm.40.139
Saito H., Morizane T., Watanabe T., Kagawa T., Miyaguchi S., Kumagai N., Tsuchimoto K., Tsuchiya M.
Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5.
Keio J. Med. 40:139-145(1991)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=20069059; DOI=10.1155/2010/437143
Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J. Biomed. Biotechnol. 2010:437143-437143(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-8024
BCRC; 60223
BCRJ; 0274
CLS; 300315/p526_PLC-PRF-5
ECACC; 85061113
IFO; IFO50069
IZSLER; BS TCL 122
JCRB; JCRB0406
KCB; KCB 200785YJ
KCLB; 28024
NCBI_Iran; C145
TKG; TKG 0376
Cell line databases/resources CLDB; cl3914
CLDB; cl3915
CLDB; cl3916
CLDB; cl5248
CCLE; PLCPRF5_LIVER
CCLE; ALEXANDERCELLS_LIVER
CCRID; 3111C0002000000071
CCRID; 3131C0001000700119
CGH-DB; 9070-4
GDSC; 925349
LINCS_LDP; LCL-1942
TOKU-E; 2898
Ontologies BTO; BTO:0003492
BTO; BTO:0004274
CLO; CLO_0008458
CLO; CLO_0008459
EFO; EFO_0006291
MCCL; MCC:0000384
Biological sample resources BioSample; SAMN03471130
BioSample; SAMN03473236
Chemistry resources ChEMBL-Cells; CHEMBL3308140
ChEMBL-Targets; CHEMBL1075561
Gene expression databases GEO; GSM207051
GEO; GSM565881
GEO; GSM827153
GEO; GSM886865
GEO; GSM887520
GEO; GSM887930
GEO; GSM888602
GEO; GSM936773
Polymorphism and mutation databases Cosmic; 721061
Cosmic; 808505
Cosmic; 871514
Cosmic; 873402
Cosmic; 925349
Cosmic; 945155
Cosmic; 948065
Cosmic; 1019318
Cosmic; 1351513
Cosmic; 1518224
Cosmic; 2023861
Cosmic; 2162538
Cosmic; 2321033